Sign inJoin waitlistJoin the waitlist

RA

Richard Ambinder

Professor of Oncology, Hematologic Malignancies · Johns Hopkins Bloomberg School of Public Health

Credentials: · · · · ·

History

Johns Hopkins Bloomberg School of Public Health
Present

Medical Oncology
1982–1984
Internal Medicine
1979–1982
Johns Hopkins Univ Sch of Med
1975–1979

Research

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Biology of Blood and Marrow Transplantation · 2008 · 1,627 citations
Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide
New England Journal of Medicine · 1986 · 553 citations
Epstein-Barr virus in AIDS-related primary central nervous system lymphoma
The Lancet · 1991 · Last of 8 authors · 456 citations

EF
Ephraim Fuchs
60 papers
LS
Lode Swinnen
57 papers
Leo Luznik
55 papers
JM
Javier Meade
53 papers
CH
Carol Huff
46 papers
DG
Douglas Gladstone
43 papers
IB
Ivan Borrello
40 papers
Robert Brodsky
38 papers
NW
Nina Wagner-Johnston
37 papers · 2 as a fellow
YK
Yvette Kasamon
35 papers
RM
Risa Mann
31 papers
William Matsui
31 papers

Grants

Enrichment for Tumor-Derived Cell-Free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma
National Cancer Institute · U01
Contact PI · $1M · Johns Hopkins University
2024–2029
Investigating the EBV Methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva
National Cancer Institute · U01
Contact PI · $2.7M · Johns Hopkins University
2023–2028
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
National Cancer Institute · R01
Contact PI · $4.3M · Johns Hopkins University
2020–2025
Clonal Immunoglobulin DNA and Lymphoma Diagnosis
National Cancer Institute · R21
Contact PI · $317.1K · Johns Hopkins University
2020–2022

Clinical trials

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)
Principal investigator · Active not recruiting · Phase 1
Catherine Bollard
2020–2026
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
Principal investigator · Terminated · Early phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014–2016
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
Principal investigator · Completed · Early phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2013–2021
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide
Principal investigator · Terminated · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2011–2016